Alkem Laboratories has officially announced the launch of Renocia Cyclical Therapy, a scientifically-designed nutritional supplement kit to support hair growth, strengthen hair follicles and manage hair loss. The company made the announcement through a press release filed under Regulation 30 with stock exchanges.

Product Specifications and Design

The Renocia Cyclical Therapy kit incorporates several key features designed for comprehensive hair growth support:

Innovative Weekly Protocol

The supplement kit features a distinctive weekly plan structure with nutritional supplements to be taken on designated days of the week. This structured weekly protocol enables better nutrient absorption and utilisation, with each supplement containing specific vitamins, minerals, and amino acids designed to align with the body's natural nutritional requirements.

Management Commentary

Commenting on the launch, Dr. Vikas Gupta, Chief Executive Officer of Alkem, highlighted the strategic approach behind the product development. He emphasized that nutritional supplementation plays an important role in hair health, and Renocia cyclical therapy offers a structured and targeted approach through the week. The CEO noted that by using only vegetarian-sourced ingredients, the company aims to make the product acceptable and accessible to all sections of the Indian population.

Market Positioning and Portfolio Integration

The launch demonstrates Alkem Laboratories' strategic expansion within its dermatology segment, which includes skin and hair care products. Under the Renocia brand, the company already offers several hair care products including hair revitalizing shampoo, conditioner, serum, and oral supplements. The new cyclical therapy kit adds a prescription-based nutritional supplement option to this existing portfolio.

For convenience and better adherence, the product is available in a wallet pack format with clear descriptions of which tablets need to be taken on each day of the week, addressing both efficacy and user compliance in the hair care supplement market.

Alkem Laboratories Limited has received a GST demand order from statutory authorities totaling ₹2.18 crores for the period covering 2018-2019 to 2020-2021. The pharmaceutical company disclosed this development under Regulation 30 of SEBI LODR Regulations on January 1st, 2026.

GST Demand Order Details

The order was issued by the Deputy Commissioner, CGST & Central Excise Division – I, Lucknow, and was received by the company on December 31st, 2025. The demand pertains to the company's Uttar Pradesh GSTIN operations during the specified period.

Nature of Alleged Violation

The demand order primarily alleges excess availment of Input Tax Credit under the applicable provisions of the IGST Act, 2017. This relates to the company's GST compliance during the three-year period from 2018 to 2021.

Alkem Laboratories has clearly stated in its disclosure that it does not agree with the demand order and the allegations contained therein.

Company's Response and Next Steps

The company has indicated it is in the process of taking appropriate legal action to contest the order. This includes filing an appeal against the GST demand order through proper legal channels.

According to the company's assessment, there is no material impact expected on its financial, operational, or other activities as a result of this GST order. The disclosure was made in compliance with SEBI regulations to keep stakeholders informed of significant regulatory developments.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 read with Schedule III of SEBI LODR Regulations. The company has also made this information available on its official website at www.alkemlabs.com for public access and transparency.